logo
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

WASHINGTON (AP) — Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy.
The highly unusual move is a latest in a string of events that have hammered the company's stock for weeks and recently forced it to lay off 500 employees. The company's decision not to comply with the FDA also places future availability of its leading therapy, called Elevidys, in doubt.
The FDA said in a statement Friday night that officials met with Sarepta and requested it suspend all sales but 'the company refused to do so.' The agency has the authority to pull drugs from the market, but the cumbersome regulatory process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply.
'We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges,' FDA Commissioner Marty Makary said in a statement.
Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects males, though it has faced scrutiny since its clearance in 2023. The one-time treatment received accelerated approval against the recommendations of some FDA scientists who doubted its effectiveness.
The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, including those who can no longer walk. Previously, it was only available for younger patients who were still walking.
Sarepta said Friday that its scientific review showed 'no new or changed safety signals' for younger patients with Duchenne's who have earlier stages of the disease. The company said it plans to keep the drug available for those patients.
'We look forward to continued discussions and sharing of information with FDA,' the company said in a statement.
Sarepta halted shipments last month of the therapy for older boys with Duchenne's, which gradually destroys muscle and skeletal strength, resulting in early death. The move followed the deaths of two teenage boys taking the therapy.
The company also confirmed a third death Friday: a 51-year-old patient who was taking an experimental gene therapy in a trial for a different form of muscular dystrophy. Sarepta said it reported the death to the FDA on June 20. The FDA said Friday it placed that trial on hold.
Sarepta noted that the gene therapy involved in the incident uses 'a different dose and is manufactured using a different process,' than Elevidys.
All three patient deaths were linked to liver injury, a side effect noted in Sarepta's prescribing information.
Earlier this week Sarepta announced it would add a bold warning to drug and lay off a third of its employees. The company did not mention the third patient death in its news release or conference call announcing those changes, sparking pointed criticism from Wall Street analysts.
Company shares fell more than 35% Friday to close at $14.07.
Cambridge, Massachusetts-based Sarepta has received FDA approval for three other Duchenne's drugs since 2016, none of which have been confirmed to work. The company has long been criticized for failing to complete several studies needed to secure full FDA approval of its drugs.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ben Askren released from hospital after grueling double-lung transplant recovery
Ben Askren released from hospital after grueling double-lung transplant recovery

Fox News

time11 minutes ago

  • Fox News

Ben Askren released from hospital after grueling double-lung transplant recovery

Former UFC fighter Ben Askren announced he was released from a hospital Tuesday after a battle with severe pneumonia led to a double-lung transplant. The 40-year-old Askren posted a video update from his vehicle, which his wife Amy was driving after he was released from the hospital. On "day 59," Askren explained how he lost 50 pounds while being hospitalized. Even worse, he described coming close to dying. "I'm out, with my beautiful wife. Supportive. Man, that was a long journey, and it's not over because I still can't really walk," Askren said in the video. "I [have to] keep reteaching myself to do that, among many other things. I guess I can make light of it because it was me, and I don't really remember it. But Amy, how close was I to dying?" After a pause, Askren's wife responded, "Too close. A few times." "Ah, man," Askren continued. "I don't remember 35 days of this journey, but I think surgery was 24-25 days ago. It was hard, it was hard. And I said this already in one of my videos, but the support you guys gave me, whether it was sending a GoFundMe, whether it was helping my kids and wife get through it – I had friends from all over the country come to visit and hang out for a couple of days – it meant so much. It was so great to just have all this support and all the love, and hopefully I'm not in this situation again for a really, really, really long time. I plan on living a while. "So, thank you guys, again. All the positive support. All the comments online. Everything. It means so much. Love you guys." In a previous video, Askren said it was "like a movie" that he didn't remember anything from May 28 to July 2. I only died four times, where the ticker stopped for about 20 seconds," he said. "But I got the double lung transplant. I made it out to the other side of it. Gaining quite a bit of strength. Learning to use everything again. I was on the scale yesterday, 147 pounds. I haven't been 147 pounds since 15 years old. … So, that was a battle. I don't remember most of it." Amy Askren said in early July her husband received a donor for the double lung transplant and was asking for prayers. Askren recently signed with Real American Freestyle, the Hulk Hogan venture hoping to popularize professional freestyle wrestling. The 40-year-old was an NCAA champion in the 170-pound division in 2006 and 2007 and competed for Team USA in the 2008 Olympics. He won gold medals at the 2005 Pan American Championships and the 2009 World Championships. Askren fully transitioned to MMA fighting when he debuted in Bellator in 2010. He competed in ONE Championship before moving to the UFC. Askren fought Robbie Lawler and won by submission at UFC 235 before falling to Jorge Masvidal. Then, in 2021, Askren fought Jake Paul in a boxing match, and he was knocked out in the first round.

A Multi-State Salmonella Outbreak Is Linked to These Frozen Beans — Are They in Your Freezer?
A Multi-State Salmonella Outbreak Is Linked to These Frozen Beans — Are They in Your Freezer?

Yahoo

timean hour ago

  • Yahoo

A Multi-State Salmonella Outbreak Is Linked to These Frozen Beans — Are They in Your Freezer?

To date, there have been 11 confirmed illnesses across 10 states. The U.S. is experiencing a massive Salmonella outbreak, and the U.S. Food and Drug Administration (FDA) believes it has finally pinpointed the to the FDA, the outbreak was first identified in October 2024, following the first reported case of illness. The most recent individual to fall ill as part of the outbreak was on June 24. The FDA revealed on July 17 that the source of the outbreak is Chetak LLC's Deep-brand frozen sprouted mat (moth) beans and frozen sprouted moong (mung) beans. The agency identified the problem through routine sampling. "The product samples tested positive for Salmonella, and whole genome sequencing analysis determined that the Salmonella present in the samples matched the strain causing illnesses in this outbreak," the FDA added. It noted that, to date, 11 people have been reported ill in connection with the outbreak from 10 different states, including Connecticut, Florida, Illinois, Massachusetts, Minnesota, New Jersey, Pennsylvania, Tennessee, Virginia, and Washington. In response to the news, the brand and the FDA issued a recall notice for several of its products. The recall includes the following:Deep-brand Sprouted Mat (Moth) in one-pound (454 grams) packages with the following lot codes printed on the back side of the bag: IN 24330, IN 25072, IN 25108, IN 24353, IN 25171, IN 24297, IN 25058, IN 25078, IN 24291, IN 25107, IN 24354, IN 24292 Related: America Has a Growing Food Safety Crisis No One Is Talking About Deep-brand Sprouted Moong (Mung) in one-pound (454 grams) packages with the following lot codes printed on the back side of the bag: IN 24330, IN 25072, IN 25108, IN 24353, IN 25171, IN 24297, IN 25058, IN 25078, IN 24291, IN 25107, IN 24354, IN 24292 Salmonella, the FDA explained, is a "group of bacteria that can cause gastrointestinal illness and fever called salmonellosis." It added that it can spread through food handlers who "do not wash their hands and/or the surfaces and tools they use between food preparation steps, and when people eat raw or undercooked foods." While most people infected with Salmonella recover without treatment, those with weakened immune systems, children, or the elderly are especially vulnerable to severe cases. Usually, symptoms appear within 12 to 72 hours after infection and can include diarrhea, fever, and abdominal cramps, according to the FDA. Though more severe cases of salmonellosis may involve a "high fever, aches, headaches, lethargy, a rash, blood in the urine or stool, and in some cases may become fatal." According to the U.S. Centers for Disease Control and Prevention, "approximately 450 persons in the United States die each year from acute salmonellosis." If you've purchased the product, the FDA recommends that you discard it immediately. If you've already consumed the product and become ill, contact your healthcare provider right away. Read the original article on Food & Wine Solve the daily Crossword

What causes Parkinson's disease? Scientists uncover an unexpected new clue.
What causes Parkinson's disease? Scientists uncover an unexpected new clue.

Yahoo

timean hour ago

  • Yahoo

What causes Parkinson's disease? Scientists uncover an unexpected new clue.

More than 10 million people worldwide are living with Parkinson's disease, a progressive neurodegenerative disorder that leads to symptoms such as tremors, slow movement, limb stiffness, and balance issues. Scientists still don't know what causes the disease, but it's thought to develop due to a complex mixture of genetic and environmental factors, and treatment is still quite limited. But new research is putting scientists one step closer to some possible answers. In a recent study published in JCI Insight, researchers found a common virus, called human pegivirus (HPgV), in the brains of patients who had Parkinson's disease when they died. Although HPgV infections don't usually cause symptoms, researchers believe the virus may be playing a role in the development of Parkinson's. 'The hypothesis is that a long-term, low-burning infection might lead to these sorts of diseases,' such as Parkinson's disease and other neurodegenerative disorders, says Barbara Hanson, a researcher at Northwestern University Feinberg School of Medicine, and one of the authors of the paper. Here's what we know so far. Over 500 viruses screened In this study, researchers screened for over 500 viruses in the autopsied brains of 10 patients who had Parkinson's disease and compared them to the autopsied brains of 14 control patients, who were matched for age and gender. In five of the patients with Parkinson's, they found the presence of HPgV, while none of the control patients had the virus. In order to bolster their findings, researchers conducted follow-up experiments that looked at the blood samples of patients who were in different stages of Parkinson's disease. What they found was that patients who had Parkinson's and were positive for HPgV had similar immune system responses, including a lower level of an inflammatory protein called IL-4, which can either promote or suppress inflammation depending on the situation. They also found that patients who had a specific Parkinson's-related gene mutation had a different immune system response to HPgV, compared to patients with Parkinson's who didn't have the mutation. 'It was a very thorough study,' says Margaret Ferris, a neurologist and researcher at Stanford University who was not part of the study. She adds that this offers a possible mechanism for the interaction between genetics and environment. Why Parkinson's disease is so hard to study Although the presence of HPgV in the brains of people with Parkinson's disease is suggestive of a link, the full answer of what causes the neurodegenerative disease is more complex. Parkinson's disease has always been hard to study, due to the fact that it develops slowly, over many years, and is difficult to diagnose in the earlier stages. 'One of the hard things about investigating neurodegenerative disorders is that it is very hard to identify people who will get neurodegenerative disorders, but don't yet have them, and to study and watch them,' Ferris says. Further complicating this matter is the fact that there doesn't seem to be one single trigger for Parkinson's disease. 'It is difficult to determine the causes of Parkinson's, because they are likely multifactorial,' says William Ondo, a neurologist at Houston Methodist Hospital, who specializes in treating patients with movement disorders such as Parkinson's disease. Ondo was not part of the study. Currently, Parkinson's disease is believed to develop from a complex mixture of genetic and environmental factors, with individual triggers varying from one person to another. This makes studying the potential causes of the disease quite challenging, and means that there still aren't definitive answers to what can trigger the condition. It's likely that some people may develop Parkinson's disease as a result of multiple triggers. 'Everyone is on their own path,' to developing Parkinson's disease, says Erin Furr-Stimming, a neurologist at McGovern Medical School at UTHealth Houston, who was not part of the study. Link between viral infections and neurodegeneration In recent years, there has been a growing body of evidence to suggest a link between viral infections and the development of neurological diseases, such as multiple sclerosis, Alzheimer's, and Parkinson's. This includes the recent discovery that Epstein-Barr virus is a major trigger for multiple sclerosis, as well as a number of associations between viral infections and neurodegenerative conditions. Parkinson-like symptoms have also been triggered by a number of viral infections, such as West Nile virus, St. Louis Encephalitis virus, and Japanese Encephalitis B Virus. As Hanson notes, inflammation in the brain has been linked to the development of neurodegenerative disorders, with viral infections being a potential trigger for this inflammation. 'Any amount of inflammation in the brain can trigger a number of cascades that lead to the loss of normal homeostatic brain function,' Hanson says. 'It's possible that viral infections are one of those triggers that lead to inflammation in the brain.' Other potential reasons that viral infections may lead to neurodegeneration include direct damage to neurons from the virus, or the accumulation of misfolded proteins. However, while this recent study offers evidence of a suggested link between HPgV and the development of Parkinson's disease, there's still more research needed before a clear link between the two can be established. 'This study doesn't show a cause-and-effect relationship—it just suggests there may be a relationship between pegivirus and Parkinson's,' says Joseph Jankovic, a neurologist and director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine. In order to understand the connection further, Jankovic says, 'this study needs to be replicated in a different cohort of patients.' Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store